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Figure S1. A) Snapshot of the VEGF-A promoter. The amplicon used for bisulfite DNA methylation analysis is 
shown in green, the ZF binding site in red and the qPCR amplicons in the promoter are shown in black. Also 
compare Fig. 2B. Potential transcription factors binding sites surrounding the ZF binding site within 500 bps were 
identified in the JASPAR database (http://jaspar.binf.ku.dk/) and sites with relative profile scores above 95% are 
indicated in grey. B) Representative examples of FACS analyses of infected and uninfected SKOV3 cells 
determined 5 days after adenoviral infection. GFP fluorescence showed consistently >95% fraction of infected 
cells. 
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Figure S2. A) Time dependent deposition and loss of DNA methylation analyzed by bisulfite sequencing in five 
experiments. Each row indicates one sequenced clone, and each column indicates one CpG site. The blue and red 
color display unmethylated and methylated CpGs, respectively. B) Graphical representation of the data shown in 
A. Compilations of these data are shown in Figure 2B and C. 
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Figure S3. Control experiments demonstrating the specificity of the targeted DNA methylation. A) Similar GFP 
fluorescence at day 5 between the ZF-Dnmt3a-CD WT and E752A inactive mutant. B) Quantification of SDHA 
normalized VEGF-A expression of ZF, ZF-Dnmt3a-CD wild type and inactive mutant at day 5. The averages and 
SEM are based on 2-3 biological repeats. C) Lack of DNA methylation of different controls indicates the 
specificity of DNA methylation deposition. 
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Figure S4. Control experiments demonstrating the specificity of the targeted histone H3K9 methylation. A) 
Similar GFP fluorescence at day 5 between the ZF-GLP-CD and ZF-GLP-CD inactive mutants. B) Quantification 
of SDHA normalized VEGF-A expression of ZF, ZF-GLP-CD wild type and inactive mutants at day 5. The 
averages and SEM are based on 2-3 biological repeats. 
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Figure S5. Nucleosome mapping quantified by MNase-qPCR shows no notable changes in nucleosomal 
occupancy. The averages and SEM are based on 2 biological repeats. 
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Figure S6. Time course of targeted deposition, spreading and loss of histone H3K9me3 methylation in control 
experiments. The red box denotes the zinc finger binding site, whilst the black boxes denote the amplicons used 
for ChIP-qPCR. The numbers above the bars show the distance of the qPCR amplicons upstream and downstream 
from the zinc finger binding site. A) ChIP-qPCR measurements of the VEGF-A locus for H3K9me3 presence in 
cells infected with ZF-GLP-CD. B) ChIP-qPCR measurements of the VEGF-A locus for H3K9me3 presence in 
cells infected with GLP-CD-only. C) ChIP-qPCR measurements of the VEGF-A locus for H3K9me3 presence in 
cells infected with ZF-only. The averages and SEM are based on 2-3 biological repeats. 
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Figure S7. Time course of targeted deposition, spreading and loss of histone H3K9me2 in control experiments. 
The red box denotes the zinc finger binding site, whilst the black boxes denote the amplicons used for ChIP-
qPCR. The numbers above the bars show the distance of the qPCR amplicons upstream and downstream from the 
zinc finger binding site. A) ChIP-qPCR measurements of the VEGF-A locus for H3K9me2 presence in cells 
infected with ZF-GLP-CD. B) ChIP-qPCR measurements of the VEGF-A locus for H3K9me2 presence in cells 
infected with GLP-CD-only. The averages and SEM based on 2-3 biological repeats. 
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Figure S8. Absence of detectable cross-talk between DNA and H3K9 methylation. A) Targeted deposition of 
DNA methylation does not lead to subsequent histone H3K9me3. B) Additional bisulfite sequencing data showing 
absence of DNA methylation under conditions of dense H3K9me2/3 methylation (after transfection with ZF-GLP-
CD). These results indicate that targeted deposition of histone H3K9 methylation does not lead to subsequent 
DNA methylation. 
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Figure S9. Peptide array specificity analyses of the antibodies used in this study. The peptide spots are annotated 
on the left side of the glass slide and the color coded boxes show the presence of the designated modified peptides. 
A) The first antibody (upper panel) bound primarily to H3K9me3 harboring peptides, with minor cross-specificity 
to H3K27me3 and H4K20me3. The second antibody (lower panel) bound to the targeted H3K9me3, but also 
showed notable cross-specificity with H4K20me3 peptides and minor cross-specificity with H3K27me3 peptides. 
B) The H3K9me2 antibody bound primarily to H3K9me2 peptides, with some cross-reactivity to H3K9me1 
peptides. C) The anti-H4-pan-Ac antibody exhibited binding to acetylated H4 peptides, with minor cross-
reactivity to H2A acetylated peptides. 
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Table 1. List of primers used in nChIP-qPCR covering the VEGF-A locus. 
 
  
Name Primer sequences 
-4896 bp FP 5-GTAGTCCCAGGGTGCAACAC-3 
RP 5-GACTGGCTAGAATGGGCATC-3 
-890 bp FP 5-GCAGTCACTAGGGGGCGCTC-3 
RP 5-CAACGCCCTCAACCCCAC A-3 
-650 bp FP 5-CCTAGCAAAGAGGGAACGGCT-3 
RP 5-AGCCTGAAAATTACCCATCCGC-3 
-189 bp FP 5-CGGTGCTGGAATTTGATATTCATTGAT-3 
RP 5-TTCAAGTGGGGAATGGCAAGC-3 
+36 bp FP 5-ACAGGGGCAAAGTGAGTGAC-3 
RP 5-GCGGTGTCTGTCTGTCTGTC-3 
+205 bp FP 5-CGCACTGAAACTTTTCGTCCA-3 
RP 5-CTCCTCCCCCTCCTCCGG-3 
+3529 FP 5-GAAGCATTCTGGGGTTTTCC-3 
RP 5-GCACAGAATATGCCCACCAC-3 
+7275 FP 5-GGTCTTGCCTTCTGTGGAGA-3 
RP 5-ACACAGGCATCCATCTGTCC-3 
+11266 FP 5-GGGGTGTTGCATGGTGATTTTTT-3 
RP 5-TGCGGATCTTGTACAAACAAATGC-3 
+13854 FP 5-GCCCTAACCCCAGCCTTTGTTT-3 
RP 5-GTATCGATCGTTCTGTATCAGTCTTTCC-3 
Sat α FP 5-ATCGAATGGAAATGAAAGGAGTCA-3 
RP 5’-GACCATTGGATGATTGCAGTCA-3’ 
Gene desert chr.12 FP 5-GCTGTTACTTTTTACAGGGAGTTTTTA-3 
RP 5-ATAAAGCAGGTAAAGGTCCATATTTC-3 
HOXA11 FP 5-TTTCCACAGCCTTTGCAGGCG-3 
RP 5-TTCAGGCTGCAAGAAGAAGCGGAG-3 
PABPC1 FP 5-TGACACAGAGCCAGAAGTTGTAAAA-3 
RP 5-CATGCATTGATACATCCTGCCTAA-3 
 12 
Table 2. P-values of ChIP-qPCR signals for the different amplicons shown in Fig. 3A and B. The p-values refer 
to the comparison of the signals at day 5 with signal in native state or at day 3, day 10 or day 15. 
 
H3K9me2 antibody 
Amplicon Native Day3 Day10 Day 15 
-4896 7.46E-03 8.67E-03 5.91E-02 1.24E-02 
-890 1.70E-02 3.13E-03 5.00E-02 4.04E-03 
-650 2.12E-02 4.36E-03 5.89E-01 5.08E-02 
-189 7.77E-10 4.90E-08 4.74E-08 3.83E-09 
+36 1.16E-03 3.31E-04 1.44E-01 1.28E-03 
+205 3.22E-04 4.27E-04 2.92E-02 3.06E-04 
+3529 9.34E-07 1.65E-07 1.52E-05 5.79E-07 
+7275 1.93E-02 1.05E-02 7.35E-02 1.77E-02 
+11266 4.64E-03 1.61E-03 1.16E-02 1.48E-03 
+13854 1.38E-03 7.73E-04 2.48E-03 1.21E-03 
 
 
H3K9me3 antibody 
Amplicon Native Day3 Day10 Day 15 
-4896 1.84E-04 1.73E-03 1.92E-04 2.81E-04 
-890 2.46E-01 6.44E-01 3.64E-05 9.18E-06 
-650 1.72E-03 8.03E-02 5.44E-03 9.87E-04 
-189 8.85E-07 1.14E-05 1.53E-06 9.36E-07 
+36 2.20E-03 8.19E-03 6.18E-04 5.49E-03 
+205 6.29E-08 9.47E-07 2.46E-09 2.43E-08 
+3529 4.01E-03 3.41E-03 3.28E-04 3.79E-05 
+7275 1.79E-02 1.13E-02 1.80E-03 7.40E-04 
+11266 4.05E-04 4.69E-03 4.95E-04 1.11E-04 
+13854 8.81E-04 8.10E-03 9.57E-05 2.58E-05 
 
